Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
   By Ben Fox Rubin 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at

Order free Annual Report for Celgene Corp.

Visit or call +44 (0)208 391 6028

React to this article
1d ago CELGENE : Additional Analyses of High-Risk Patients from Phase III Study AML-001..
1d ago CELGENE : New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia ..
1d ago CELGENE : Results from Phase III Study of REVLIMID® Lenalidomide Demonstrating I..
1d ago CELGENE : Combination of ISTODAX® romidepsin and Standard CHOP Demonstrates a Co..
1d ago CELGENE : REVLIMID® Lenalidomide Single-Agent and Combination Studies in Mantle ..
1d ago CELGENE : New Data in Myelodysplastic Syndromes Presented at the 56th American S..
2d ago CELGENE : Data Presented on REVLIMID® (lenalidomide) Compared with Investigators..
2d ago CELGENE : Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plu..
6d ago CELGENE : Releases Data from Phase 1b/2 Study of ISTODAX
7d ago CELGENE : Releases Results from Stratus Trial
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes